CYP19A1 and breast cancer: In a preclinical study, researchers found the HDACi entinostat (ENT) increased the expression of estrogen receptor-α (ERα) and aromatase in breast cancer cells and restored the sensitization of breast cancer cells to the aromatase inhibitor letrozole both in vitro and in vivo.